Clinical Trial Update: Risk Stratified Sequential Treatment for CD20-positive PTLD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on risk-stratified sequential treatment for CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Posttransplant Lymphoproliferative Disorder

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: PTLD, Posttransplant Lymphoproliferative Disorder | Phase 2 | Status: COMPLETED